ISM4808

Asset

Oral PHD1/2 inhibitor that raises the body's own erythropoietin and improves iron use

Stage: Phase 1
Modality: Small molecule
Target: EGLN1; 1
Indication: 1
Trial: 1
Developer

Indications

1

Anaemia of chronic kidney disease
Phase 1, Not yet recruiting, NCT07415304, clinicaltrials.gov, 8 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners2
Trials1
Evidence for its targets2
Competitors1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.